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ABSTRACT  
Autoimmune hepatitis (AIH) is a complex autoimmune disease characterized by immune-mediated 
destruction of hepatic parenchyma which can result in cirrhosis, liver failure, and death. Current AASLD 
and EASL guidelines recommend corticosteroids alone or in combination with azathioprine as first-line 
treatment strategies. However, a significant proportion of patients may not be able to tolerate or achieve 
complete biochemical response with these options. In this article, we discuss approaches to these patients 





















Autoimmune hepatitis (AIH) is a female predominant condition characterized by immune-mediated 
destruction of liver parenchyma and presence of peripheral autoantibodies (1,2). Waldenström first 
described this disease in a group of young females with hypergammaglobulinemia over 60 years ago (3). 
Despite forward progress in diagnosis and therapeutic strategies, variable clinical and phenotypic 
presentations have prevented the formation of standardized algorithmic treatment for all patients. Similar 
to other autoimmune liver diseases (4,5) all AIH is not the same; high risk populations such as African 
Americans (6), or those with early disease onset (7,8), incomplete normalization of liver tests(7), and 
advanced disease at diagnosis (8,9) have worse overall survival. 
AIH was the first chronic liver disease in which medical treatment was associated with improved 
survival (10), yet an individualized therapeutic approach has not yet been established. Management 
principles even among experts in this evolving field remain heterogeneous especially beyond accepted first-
line therapies. Much like any rare disease, the variation in therapeutic approaches are the result of small 
retrospective studies, poor understanding of disease associated immunologic mechanisms, and wide 
knowledge gaps in disease pathogenesis. The clarification of evidence-based strategies is paramount, as  
recent epidemiologic data suggest a rising incidence of AIH (11).  
Strategic AIH goals of normalization of liver inflammation, prevention of subsequent parenchymal 
insult, and inhibition of fibrosis progression or reversal of existing scar are similar to those of any chronic 
liver disease. This review will highlight these therapeutic aims while clarifying the approach to challenging 
groups of adult AIH patients.  
  
BEYOND GUIDELINE RECOMMENDED FIRST-LINE TREATMENT STRATEGIES 
 The current American Association for the Study of Liver Diseases (AASLD) and European 
Association for the Study of Liver (EASL) recommend treatment of disease-related inflammation with 
either high-dose corticosteroids alone or in combination with Azathioprine (AZA) (1,12).  Therapeutic 
endpoints have become more stringent in updated guidelines, and treating clinicians should now target 
normalization of both aspartate aminotransferase (AST) and alanine aminotransferase (ALT) as well as 
immunoglobulin G (IgG) in order to optimize transplant-free survival (7). Unfortunately, not all AIH 
patients will have favorable biochemical responses to first-line regimens because of medication intolerance 
(10%) (12), incomplete  response (15%) (12,13), and treatment failure (9%) (14).   
 
TREATMENT INTOLERANT 
The inability to normalize liver transaminases and IgG due to intolerance (side effects) of 
medication requires urgent exploration of other treatment agents given the increased risk of fibrosis 
progression and worse survival (15,16). Fortunately, AIH maintenance armaments have expanded in recent 
years, and multiple reports of nonstandard therapies in challenging patient groups are available. Intolerance 
to recommended first-line therapy, AZA and prednisone, is a significant cause for cessation of therapy in 
up to 10% of patients related to physical, somatic, or hematologic findings (12).  
 
There is currently no consensus on the optimal second-line choice for AZA intolerance, but 
mycophenolate mofetil (MMF)has been the most studied second-line agent, and observational data suggests 
it is tolerated in 54-74% of patients in this group (17,18) (20,21). However, 6-mercaptopurine (6-MP), a 
molecule formed from non-enzymatic degradation of the nitroimidazol group from AZA, could also be a 
viable treatment strategy subsequent to AZA because of retained immunosuppressive properties (Table 1).  
In  studies of inflammatory bowel disease, up to 60% of patients intolerant to AZA are able to tolerate 6-
MP (19,20).  A recent study by Hübener et al (13) retrospectively examined 20 AZA-intolerant AIH 
patients, largely from gastrointestinal side effects, from two large European referral centers.  6-MP was 
tolerated well by 15 (75%) patients, and resulted in complete and partial biochemical response in 8 and 7 
patients respectively.   Therefore, 6-MP may have tolerance rates similar to MMF, and could be considered 
as an option for this group of patients (1,12). We prefer challenging AZA-intolerant patients with 6-MP 
(25mg daily and increasing to 50mg daily if tolerated) , as it remains an alternative that could help avoid 
risk of teratogenicity in females that are pregnant or become pregnant while taking MMF as well as provide 
cost-savings. Furthermore, as a downstream immunologically active product of the AZA, 6-MP may 
provide much of the survival benefits as its well-studied parent compound.    
Patients with intolerance or drug-induced complications from systemic corticosteroids therapy (21) 
are also a challenging cohort of patients with difficult to treat AIH (Table 1). Corticosteroids have shown 
survival benefit with or without AZA since the 1960s, yet AZA alone for induction therapy was associated 
with an excess of mortality in early clinical trials (10,22). Budesonide, a next-generation corticosteroid, 
may have a critical role in those with systemic corticosteroid contraindications such as patient with 
osteoporosis, poorly controlled diabetes or hypertension, or unstable mental illness. The results from a 6-
month, blinded, phase IIb trial including AIH patients without cirrhosis on budesonide (3mg, either 3 times 
or 2 times daily) and AZA was published in 2010 (23) . In 6 months, the budesonide and AZA combination 
resulted in  both higher frequency of normalized liver tests (60% vs 38.8%) and less steroid related side 
effects (28% vs 54.4%) compared to standard therapy with prednisone and AZA. This only prospective 
randomized control trial with budesonide was criticized because of lower than expected remission rates on 
prednisone that may have been due to scheduled prednisone weaning, a relatively low dose of prednisone 
in the control arm, short term follow-up, and no histologic comparison of outcomes. Mindful application 
of budesonide in AIH requires consideration of no defined long-term outcomes, unclear dose-scheduling, 
and contraindication in patients with cirrhosis and those with portosystemic collaterals (1). We have 
observed good response rates in some AIH patients treated with combination therapy including budesonide 
in place of prednisone. However, we have also witnessed a few incomplete responses despite optimization 
of the maintenance agent, and agree with the most recent EASL guidelines that a change to systemic 
corticosteroids is commonly beneficial in this group.   
 
INCOMPLETE AND NON-RESPONDERS 
Incomplete response to a treatment regimen is defined by incomplete recovery of clinical 
symptoms, biochemical data (AST/ALT and IgG), and possibly histologic findings.  Current guidelines 
(1,12) suggest normalization of aminotransferases and IgG levels as a key therapeutic aim, as the clinical 
impact of incomplete response has been linked to fibrosis progression, liver-related death or requirement 
of liver transplantation (7,24,25).  
Patients are identified as incomplete responders if they fail to normalize liver tests and IgG within 
3 years according to the AASLD guidelines (12) (Table 1). It is to be determined if fulfillment of AALSD 
and EASL treatment goals have dramatic impact on long-term outcomes prospectively.  In retrospective 
reviews, it seems meeting more stringent response criteria may better predict those with excellent outcomes 
(26).  In fact, utilization of early biochemical response may have merit in this arena, as Kanzler et al 
observed that patients exhibiting a biochemical response in only 3 months have excellent long-term survival 
(27). Furthermore, incomplete normalization of ALT within 6 months of therapy in a study of 133 AIH 
patients from New Zealand was independently associated with poor outcomes (7). However, it must be 
observed that normal liver tests may not be the best surrogate for hepatic inflammation, thus disagreement 
with histologic activity is relatively common according to study by Dhaliwal et al (28).  In that study of 120 
AIH patients with normal ALT and globulin levels at 6 months, persistent histologic inflammation was 
observed in 46% of patient biopsy specimens. Furthermore, those with continued inflammation had less 
frequent regression of fibrosis and excess mortality compared to patients with histologic normalization.     
The demarcation of incomplete response requires further management considerations beyond that 
of biochemical follow-up. In fact, the failure to meet treatment goals, at treatment initiation or in follow-
up, should prompt examination for concurrent liver disease (including overlap phenomenon, Figure 1), drug 
induced liver injury, treatment compliance, inadequatepharmacologic therapy, and accuracy of diagnosis. 
Consideration of co-existent autoimmune liver diseases, primary sclerosing cholangitis (PSC) and primary 
biliary cholangitis (PBC), is necessary, particularly among individuals with evolution of cholestasis. 
Overlap phenomenon are not rare in AIH groups, as a recent cross-sectional study of over 1300 AIH patients 
from the Netherlands identified PBC and PSC in 9% and 6% of AIH patients respectively (29).  Liver 
biopsy plays an important role not only initially at the time of establishing the diagnosis of AIH, but also 
in cases with incomplete response to optimal therapy. Typical (interface hepatitis, lymphoplasmacytic 
infiltrates, hepatic rosette formation, and emperipolesis) and compatible histologic findings on liver biopsy 
are critical to confirming the diagnosis AIH (1) and clarifying the presence or absence of  alternative or 
coexisting hepatic disease.  However,there are no pathognomonic AIH features on biopsy, and histologic 
findings should lend support or opposition to diagnosis.  
Furthermore, careful exposure and drug histories (including AZA), as well as pinpointing other 
contributing comorbidities such as the metabolic syndrome should raise suspicions for additive processes 
(Table 1).  Coexisting non-hepatic conditions should also be examined and optimized in order to provide 
best care, as incomplete responders have more anxiety, depression, and avoidant relationship styles (30). 
Thus, aggressive identification and treatment of anxiety and depression, as well as the education of medical 
compliance is a critical therapeutic step in this distinct group.  
Monitoring of AZA metabolites (6-thioguanine nucleotide (6-TGN) and 6-methyl mercaptopurine 
(6-MMP)) metabolites in AZA-treated patients could also identify a proportion of patients that may be 
rescued from incomplete response with dose adjustment.  6-TGN concentrations more than 220 pmol per 
8x108 red blood cells have been associated with biochemical remission (31).  Elevated 6-MMP levels 
(>5700 pmol per 8x108) can also contribute to associated symptoms of nausea, anorexia, and influenza-like 
symptoms (32), thereby impacting compliance. Allopurinol, through inhibition of xanthine oxidase, 
represents a therapeutic approach in patients with increased 6-MMP and low 6-TGN, as it produces 
preferential AZA metabolism by the thiopurine methyltransferase enzymatic pathway towards 6-TGN (33).     
Despite elimination of contributing hepatic disease or insults, optimization of first-line therapies, 
and assurance of medical adherence, abnormal liver tests will be present in 9-34% of treated patients at 2 
years (14,27). These patients, along with those intolerant and failing (minimal clinical and laboratory 
improvement in several weeks without liver failure with standard first-line therapy(1)) standard therapy are 
candidates for alternative immunosuppressive treatments. The more common strategies including MMF, 
sirolimus/everolimus, tacrolimus, and cyclosporine have encouraging results in regard to biochemical 
improvement. However, extrapolation of these agents to practice must be cautiously undertaken as they are 
founded primarily on small retrospective case series with heterogeneous endpoints. 
MMF, a purine antagonist widely used in the setting of liver transplantation, has been utilized in a 
number of small retrospective studies including patients with AIH with AZA-intolerance, incomplete 
response, and failure (17,34,35).  MMF (goal 1,500 – 3,000 mg in divided doses per day) seems to be 
effective as a second-line agent for patients with AZA-intolerance. A small retrospective study showed that 
complete response rate was observed in 8 out of 9 patients who were intolerant to AZA (34).  In the same 
study, patients switched to MMF after treatment failure with AZA were only able to gain biochemical 
improvement, but not complete response. A similar observation was made by Hennes et al, as 75% of 
patients with AZA failure did not respond to MMF (17). Only recently has MMF been considered for first-
line AIH therapy, and results suggest it may be an effective and well tolerated medication with 88% of 
patients obtaining biochemical normalization within the first few months (36). However, there is no long-
term survival data for MMF, nor are the implications of its role as a potential teratogen during pregnancy 
commonly considered.  Utilization of MMF among women of child bearing age necessitates the 
documented discussion of increased risk of spontaneous abortion and major birth defects (37) associated 
with its use in pregnancy.  We require at risk patients to use two forms of birth control and periodic urine 
pregnancy tests. GI symptoms ( e.g., nausea, dyspepsia and diarrhea), headache, and bone marrow 
suppression are among the common side effects seen with MMF use. If supportive measures do not alleviate 
these symptoms, MMF dose reduction should be considered next. 
   Mammalian target of rapamycin (mTOR) inhibitors, such as sirolimus and everolimus, work to 
modulate the expansion and survival of activated lymphocytes. These agents were initially reported in the 
post-transplant experience with AIH (38), yet this experience led to their introduction in challenging AIH 
patients. A recent small US report included 5 AIH patients with first-line (3 patients with second-line MMF 
as well) failure treated with sirolimus (2 mg per day) and titrated trough levels of 10-20 ng/dL.  Four (80%) 
of these patients showed an improvement in liver tests and 2 (40%) patients had normalization (39). 
Similarly, everolimus showed some efficacy for AIH patients with treatment nonresponse and intolerance. 
In one study, 43% of patients had normal ALT levels and 57% had ALT levels less than 55 international 
units after 5 months of therapy (40).  While experience with mTOR inhibitors in AIH is currently limited, 
they may represent a treatment option in AIH patients with recent history of malignancy based on their anti-
proliferative effect (41),.  
 Calcineurin inhibitors, such as cyclosporine and tacrolimus, have been used longest in the treatment 
of refractory cases, yet these experiences are marked by small treatment numbers and limited follow-up 
data. The literature contains 10 reports of 133 patients utilizing cyclosporine as initial and second-line agent 
for incomplete response and failure, and has been commonly effective in over 90% of patients (42). In one 
study, 5 AIH patients with poor response to AZA and corticosteroids were treated with cyclosporine at 2 -
3 mg/kg/day which resulted in biochemical remission of 80% of patients in 3 months(43). Tacrolimus has 
also shown some benefit in this hard to treat AIH group, as studies have supported improvement by any 
measure in 98% of patients(42). The most recent experience with tacrolimus in this setting included 13 
patients with incomplete response or failure at a single large center, where 12 obtained normalization of 
liver enzymes (mean trough 6.0 ng/mL) (44).  
 
ACUTE SEVERE PRESENTATION  
Arguably one of the most challenging groups of AIH is that with acute severe hepatitis, with or 
without liver failure. There is limited literature and a common association with outcomes of death or 
transplant in these patients (45,46). The decision to pursue a course of corticosteroids remains complex, 
particularly as the subsequent determination of clinical response to treatment and the timing of listing for 
liver transplantation are unclear. Most recently, Heneghan et al published the outcomes of group of 32 acute 
severe AIH patients from the United Kingdom (no cirrhosis, but INR >=1.5 at presentation) of which, 23 
(72%) were treated with steroids (47). Approximately half of treated and all of the untreated patients 
required liver transplantation, yet there was no difference in sepsis episodes or mortality between the 
groups.  Prognostic classifications are still not available for this high risk group, yet are key as severity of 
liver failure may play a role in steroid responsiveness (48). In fact, a study of 40 South American patients 
with a fulminant AIH revealed that corticosteroid failure was much more likely among those with higher 
MELD scores and encephalopathy grade 3 or higher (49). Utilization of corticosteroids in an acute severe 
presentation, preferably at high dose intravenously, requires close observation of clinical improvement or 
deterioration and infection. Early evaluation and listing for liver transplantation should be done for patients 
presenting with acute liver failure while response to therapy is assessed.  
 
PREGNANCY  
The approach to pregnancy in AIH patients requires close attention, as disease development or flare 
during or after pregnancy can pose a significant risk to both mother and baby.  A recent report of 83 
pregnancies in 53 women with AIH revealed maternal complications and disease flares in 38% and 33% 
respectively. AIH flares (worsening liver inflammation) were more likely to occur in patients who were not 
on therapy or had a flare in the year prior to conception (50). An earlier study of 22 women with a total of 
44 pregnancies found that over half had disease flares after delivery and almost a quarter flared during 
pregnancy (51). A variety of approaches have been utilized in pregnant AIH patients prior to or at 
conception including discontinuation of all immunosuppressants or modification of long term maintenance 
medications. Pharmacologic alterations have been focused on minimizing risk to baby, however, the 
aforementioned data suggests that maternal disease control remains important throughout pregnancy and 
after delivery. AZA remains a US Food and Drug Association category D medication in pregnancy. Yet, 
multiple retrospective studies have shown no increase in birth defects, stillbirths, or fetal malformations 
with use of AZA (51–53). A similar safety profile of AZA in pregnancy has been shown among 
inflammatory bowel disease patients (54). Mindful consideration of calcineurin inhibitor use in AIH during 
pregnancy should also be exercised, as post-transplant data has suggested favorable pregnancy outcomes 
in this group including patients treated with tacrolimus (60%) and cyclosporine A (38%) (55).  
Despite the theoretical increase in anti-inflammatory cytokines secondary to rising estrogen levels 
(56), we routinely counsel pregnant or about to get pregnant patients with AIH about the risk and benefits 
of maintaining remission with AZA or corticosteroids throughout pregnancy in accordance with above data 
and current EASL guidelines (1). Optimal disease control in the year leading up to pregnancy and careful 
monitoring for disease activity after delivery are also suggested. MMF should be withdrawn prior to 
conception  and should not be used during pregnancy as it has been associated with increased 
teratogenicity(57). We try to avoid MMF use in child bearing patients, yet if necessary, we carefully counsel 
patients on the risk of this drug in pregnancy, ensure two forms of birth control, and engage in frequent 
urine pregnancy testing.  
 
ASYMPTOMATIC and ELDERLY  
Approximately one third of AIH patients will present without complaints (11,26,58), commonly 
with findings of slightly abnormal liver tests from routine laboratory work completed for other indications. 
Despite the range of clinical variability between asymptomatic and symptomatic patients at presentation, 
similar degrees of lobular hepatitis and bridging fibrosis have been observed at diagnosis. Furthermore, 
many with a mild asymptomatic presentation will become symptomatic and develop a variety of symptoms 
such as malaise, nausea, abdominal pain, pruritus, or jaundice.Left untreated, a lower overall survival can 
be expected for these patients (59). Improvement of hepatic fibrosis, including cirrhosis, in both groups is 
achievable, as observed in 57% of treated AIH patients with paired liver biopsies (60). Among those 
diagnosed and treated early, approximately 80% can expect fibrosis resulting from hepatic inflammation to 
be prevented or delayed (61).  In fact, in this study from the Mayo Clinic with 87 patients, fibrosis scores 
improved in 53% and remained stable in 26%. As expected, improvement of fibrosis scores were related to 
improvement in histological activity indices during the approximately 4-year follow-up. Therefore, we 
recommend aggressively treating patients with mild asymptomatic disease in order to minimize 
symptomatic disease, improve overall-survival, and prevent fibrosis progression.    
The decision to treat older patients with asymptomatic disease and mild inflammation is still 
debatable, as the medication risks may outweigh the theoretical benefit of treatment. One study showed 
67% overall 10-year survival of untreated mild asymptomatic patients (62). An uncontrolled study of 31 
asymptomatic patients (half did not receive therapy) showed no difference in survival among the non-
treated patients and the rest of the cohort (9). Elderly patients commonly constitute a large proportion of 
the asymptomatic patients at presentation, but have been shown to present with increased frequency of 
advanced fibrosis (62,63). We offer treatment to those with advanced fibrosis and evidence of significant 
inflammatory activity on liver biopsy.  However, in the elderly with mild activity and early fibrosis, the 
decision to treat should be carefully considered, and exercising pharmaceutical reluctance, especially 
among patients with significant co-morbidities, remains reasonable.  
 
CIRRHOSIS 
Treatment of AIH patients with advanced fibrosis and cirrhosis remains critical if not 
contraindicated by associated comorbidities. Cirrhosis at diagnosis has been observed to be a predictor of 
reduced survival, and is associated with need for liver transplantation (8). Findings of inflammatory activity 
on biopsy among patients with cirrhosis necessitates treatment, as failure to normalize histologic 
inflammation is associated with less fibrosis regression and also worsened overall-survival (28). In fact, 
improvement of fibrosis may explain previous findings of similar survival rates between patients with and 
without cirrhosis at diagnosis (64). However, we commonly withhold therapy in cirrhotic AIH patients 
without histologic inflammation on biopsy (burned out cirrhosis), as the impact in overall outcome is likely 
to be minimal at best and may even increase risk of  drug-related side effects (65,66). 
 
RECURRENT AUTOIMMUNE HEPATITIS AFTER OTHOTROPIC LIVER 
TRANSPLANTATION  
 Liver transplantation should be considered in patients with AIH when signs of fulminant failure, 
hepatic decompensation, or liver cancer occur.  The recurrence of AIH (rAIH) after transplantation is 
common and ranges from 8 to 12 percent at one year after transplantation (67). The 5-year risk of recurrence 
is 36-68%.  Despite high rate of recurrence, graft failure requiring re-transplantation occurs in only 13-23% 
and the 5-year survival of adults with recurrent autoimmune hepatitis is excellent at 89-100% (12). Given 
these statistics, the possibility of recurrence should not preclude the prospect of liver transplantation for a 
suitable candidate.  
 Particular patient populations may be at higher risk for recurrent autoimmune hepatitis after 
transplantation.  Studies show recurrent AIH tends to be more frequent in HLA-DR3–positive transplant 
recipients (68,69). HLA mismatching may be a significant factor in rAIH (70); however given the scarcity 
of organ donors, we do not recommend HLA matching for liver transplantation. A recent study 
demonstrated that severity of original disease correlates with risk of aggressive rAIH (70,71). Patients with 
higher IgG, AST and ALT are more likely to have recurrent AIH, suggesting incomplete suppression at the 
time of transplant may contribute to rAIH.        
 Diagnosis of rAIH can be difficult, as this entity may be found with normal liver tests (72). Some 
authors suggest protocol liver biopsies may be used to identify clinically silent remission(72); however this 
is not our common practice. When a biopsy is performed, histology should demonstrate interface hepatitis 
with plasma cells and lymphocytes but without endotheliaitis or ductilitis. One might expect less recurrent 
autoimmune disease since transplant patients are maintained on immunosuppressive therapy; however, 
rAIH can be more aggressive than prior to transplantation.  Many patients will require multi-drug 
immunosuppression long-term including a calcineurion inhibitor, mycophenolate and corticosteroids with 
or without an mTOR inhibitor (73).   
 
CONCLUSIONS  
AZA and corticosteroids remain a well-established and guideline driven approach to AIH treatment 
(1,12). However, second-line treatment strategies for AIH and distinctive patient groups at risk for disease 
related complications remain a major challenge. Beyond second-line therapy considerations, AIH patient 
populations such as those with an acute severe or asymptomatic presentation, pregnancy, advanced age, 
cirrhosis, and rAIH also represent special cohorts where limited study numbers have been unable to clarify 
an algorithmic approach. We propose an individualized strategy based on current literature and guidelines 
to address these difficult to manage cases.    
AIH represents a dynamic field of study with a breadth of unmet research needs. Insight into the 
nuances of AIH management may become transparent with further dissection of key genetic underpinnings 
and environmental risk factors. Until then, AIH will require continued study, collaboration of investigators, 
and access to large populations with AIH to accumulate the best clinical evidence.  Our center has formed 
the Autoimmune Hepatitis Research Network (www.facebook.com/groups/autoimmunehep) and 
Autoimmune Hepatitis Association (www.facebook.com/autoimmunehepatititsassociation and 
www.aihep.org) in 2014 with the hope that social media use as a research tool will make research 






TABLE 1: Clinical Considerations and Management Options for Difficult AIH Cases. 
 
Challenge  Considerations Management Options  
Intolerance, contraindications or 
complications from AZA 
- Compliance 
- Contributing axis disorder 
- 6-TG and 6-MMP levels 
- Medication side effect 
- 6-MP or MMF 




- Increase AZA dose if 6-TG 
levels low 
Intolerance, contraindications or 
complications from 
corticosteroids 
- Avoid in patients with poorly 
controlled diabetes or 
hypertension, unstable mental 
illness or osteoporosis 
 
- Budesonide in patients without 
cirrhosis or portosystemic 
collaterals 
Incomplete or no response to 
prednisone and AZA 
- Compliance 
- 6-TG and 6-MMP levels 
- Overlap conditions (PSC, 
PBC,     NASH) 
- Drug induced liver injury 
- Viral hepatitis 
- MMF, cyclosporine, 
tacrolimus, sirolimus, or 
everolimus 
- Overlap condition specific 
therapy 
- Stop offending drug 
 
Acute severe presentation - Assess for liver failure 
- Exclude concomitant liver 
conditions 
 
- Early evaluation and listing for 
liver transplant 
- Intravenous corticosteroids 
Pregnancy - Maintenance of remission 
- No MMF 














Figure.1. Overlap syndrome in a patient with autoimmune hepatitis, primary biliary cholangitis, and non-
alcoholic steatohepatitis. 
 Footnote: Liver biopsy showing findings of autoimmune hepatitis [portal and lobular inflammation with 
interface activity and abundant plasma cells (Figure.1 A. Small window highlights plasma cells)], primary 
biliary cholangitis [bile duct injury with lymphocytic infiltrate (Figure1.A)], and steatohepatitis 
[macrovesicular steatosis, ballooned hepatocytes with Mallory bodies, and pericellular fibrosis Figure 1. A 
and B)] with bridging fibrosis (Figure. 1. B).  
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